Spark Therapeutics reported a net loss of $32.6 million, or $1.07 per basic and diluted share, in the third quarter compared with a net loss of $16.9 million, or $0.70 per basic and diluted share, in the third quarter of 2015, according to a company press release.
Revenue was reported at $1.3 million, which the company attributed to a collaboration with Pfizer. The same amount was reported in the third quarter of 2015.
Research and development expenses were up by $10.6 million to $22.4 million compared with the third quarter of last year. General and administrative expenses were $12 million compared with $6.5 million a year ago.